JP2007503443A5 - - Google Patents

Download PDF

Info

Publication number
JP2007503443A5
JP2007503443A5 JP2006524755A JP2006524755A JP2007503443A5 JP 2007503443 A5 JP2007503443 A5 JP 2007503443A5 JP 2006524755 A JP2006524755 A JP 2006524755A JP 2006524755 A JP2006524755 A JP 2006524755A JP 2007503443 A5 JP2007503443 A5 JP 2007503443A5
Authority
JP
Japan
Prior art keywords
pyridyl
xanthine
alkyl
dipropyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006524755A
Other languages
English (en)
Japanese (ja)
Other versions
JP4769721B2 (ja
JP2007503443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/027133 external-priority patent/WO2005021548A2/en
Publication of JP2007503443A publication Critical patent/JP2007503443A/ja
Publication of JP2007503443A5 publication Critical patent/JP2007503443A5/ja
Application granted granted Critical
Publication of JP4769721B2 publication Critical patent/JP4769721B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006524755A 2003-08-25 2004-08-20 置換8−ヘテロアリールキサンチン Expired - Lifetime JP4769721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49787503P 2003-08-25 2003-08-25
US60/497,875 2003-08-25
PCT/US2004/027133 WO2005021548A2 (en) 2003-08-25 2004-08-20 Substituted 8-heteroaryl xanthines

Publications (3)

Publication Number Publication Date
JP2007503443A JP2007503443A (ja) 2007-02-22
JP2007503443A5 true JP2007503443A5 (cg-RX-API-DMAC10.html) 2007-06-14
JP4769721B2 JP4769721B2 (ja) 2011-09-07

Family

ID=34272616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006524755A Expired - Lifetime JP4769721B2 (ja) 2003-08-25 2004-08-20 置換8−ヘテロアリールキサンチン

Country Status (19)

Country Link
US (3) US7342006B2 (cg-RX-API-DMAC10.html)
EP (2) EP1658291B1 (cg-RX-API-DMAC10.html)
JP (1) JP4769721B2 (cg-RX-API-DMAC10.html)
KR (1) KR101222364B1 (cg-RX-API-DMAC10.html)
CN (2) CN1894250B (cg-RX-API-DMAC10.html)
AR (1) AR045499A1 (cg-RX-API-DMAC10.html)
AU (1) AU2004268964B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0413922B8 (cg-RX-API-DMAC10.html)
CA (1) CA2536553C (cg-RX-API-DMAC10.html)
DK (2) DK1658291T3 (cg-RX-API-DMAC10.html)
ES (2) ES2557310T3 (cg-RX-API-DMAC10.html)
IL (1) IL173723A (cg-RX-API-DMAC10.html)
NZ (1) NZ545715A (cg-RX-API-DMAC10.html)
PL (1) PL1658291T3 (cg-RX-API-DMAC10.html)
PT (1) PT1658291E (cg-RX-API-DMAC10.html)
RU (1) RU2357969C2 (cg-RX-API-DMAC10.html)
TW (1) TWI362390B (cg-RX-API-DMAC10.html)
WO (1) WO2005021548A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200602333B (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR20040080939A (ko) * 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
US7342006B2 (en) * 2003-08-25 2008-03-11 Adenosine Therapeutics, Llc Substituted 8-heteroaryl xanthines
EP1778712B1 (en) * 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CA2580860A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US20070059740A1 (en) * 2005-08-26 2007-03-15 Linden Joel M Method of targeting a2b adenosine receptor antagonist therapy
US7566401B2 (en) 2005-10-03 2009-07-28 Kelm Mark A Process for separating and isolating xanthines, individual polar protic monomers, and polar protic oligomers
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
CN101466382A (zh) 2006-06-16 2009-06-24 PGx健康有限责任公司 取代的8-[6-氨基-3-吡啶基]黄嘌呤
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en) * 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
RU2344137C1 (ru) * 2007-07-18 2009-01-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
US20110118276A1 (en) * 2008-07-16 2011-05-19 Edward Leung Methods of treating atherosclerosis
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
RU2404181C1 (ru) * 2009-06-02 2010-11-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) 3-метил-8-пиперазино-7-(тиетанил-3)-1-этилксантина гидрохлорид, проявляющий антиагрегационную и дезагрегационную активность
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
EP2499142B1 (en) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
US8940751B2 (en) 2010-09-13 2015-01-27 Advinus Therapeutics Private Limited Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
EP2465859A1 (en) * 2010-12-08 2012-06-20 Life & Brain GmbH 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
CN102532137B (zh) * 2011-12-05 2014-12-10 辽宁医学院 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4126866A1 (en) * 2020-03-26 2023-02-08 Inspyr Therapeutics, Inc. 8-substituted diaryl xanthines as dual a2a-a2b antagonists
JP2024521704A (ja) 2021-05-18 2024-06-04 アドベイト,エルエルシー A2bアンタゴニストとしての環状アミド含有ピリジルキサンチン
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
WO2024050825A1 (en) * 2022-09-09 2024-03-14 National Institute Of Biological Sciences, Beijing Compounds as mlkl inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
AU1507099A (en) * 1997-12-15 1999-07-05 Kyowa Hakko Kogyo Co. Ltd. Preventives/remedies for sleep disturbance
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
ATE319452T1 (de) * 1999-10-29 2006-03-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen essstörungen
CN1420775A (zh) * 2000-02-17 2003-05-28 Cv治疗公司 鉴定及使用a2b腺苷受体拮抗剂介导哺乳动物细胞增殖的方法
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
MXPA04004388A (es) 2001-11-09 2005-05-16 Cv Therapeutics Inc Antagonistas del receptor a2b de adenosina.
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR20040080939A (ko) * 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) * 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
US7342006B2 (en) 2003-08-25 2008-03-11 Adenosine Therapeutics, Llc Substituted 8-heteroaryl xanthines
US20060058322A1 (en) 2004-09-01 2006-03-16 Dewan Zeng Method of wound healing using A2B adenosine receptor antagonists
NZ554485A (en) * 2004-10-15 2010-12-24 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
KR101428113B1 (ko) * 2006-03-17 2014-08-07 길리애드 사이언시즈, 인코포레이티드 A2b 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina

Similar Documents

Publication Publication Date Title
JP2007503443A5 (cg-RX-API-DMAC10.html)
RU2006109474A (ru) Замещенные 8-гетероарилксантины
JP7181967B2 (ja) 一過性受容体電位a1イオンチャネルの阻害
AU761694B2 (en) QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
EP3877376B1 (en) Pyridazinone compounds and uses thereof
CA2189830C (en) Uses for corticotropin releasing factor atagonists
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
CA2290766C (en) Method of treating nitrate-induced tolerance
TW202122387A (zh) Mta協同性之prmt5抑制劑
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
JP2019535664A5 (cg-RX-API-DMAC10.html)
CA2644841C (en) Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
JP2004515550A5 (cg-RX-API-DMAC10.html)
RU2018138047A (ru) Гетероциклические вещества - агонисты gpr119
KR20060110006A (ko) 비전형 항정신병제와 코르티코트로핀 방출 인자 길항제의치료적 조합물
HRP20192151T1 (hr) Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza
JP2016537384A5 (cg-RX-API-DMAC10.html)
JP2019530708A5 (cg-RX-API-DMAC10.html)
CN101043889B (zh) A2b腺苷受体拮抗剂在制备促使伤口愈合的药物中的应用
HK40091925A (en) Pyridazinone compounds and uses thereof
RU2021138377A (ru) Производные пиридопиримидинов в качестве ингибиторов p2x3
RU2021107655A (ru) Соединения триазоло-пиримидина и их применение
HK40057226A (en) Pyridazinone compounds and uses thereof
HK40057226B (en) Pyridazinone compounds and uses thereof
JPWO2002019975A1 (ja) 育毛剤